Effect of Payment Bundling on Calcimimetic Use Still Unclear
Younger age, longer dialysis vintage, and black race are associated with greater cinacalcet prescribing in the United States.
Secondary Hyperparathyroidism
Parathyroidectomy-Associated Hyperkalemia Common in HD Patients
Hyperkalemia developed in nearly 67% of hemodialysis patients during or immediately following total parathyroidectomy with autotransplantation for secondary hyperparathyroidism.
Cinacalcet Appears Safe, Effective for Children With SHPT
In a small study, more than half of pediatric patients receiving cinacalcet experienced a 30% or greater decline in mean intact parathyroid hormone.
Cardiovascular Event Risk Higher With Total Parathyroidectomy
Patients who underwent subtotal vs total parathyroidectomy had half the risk for cardiovascular events.
Parathyroidectomy for SHPT Reduces Aortic Calcification
In a small study of hemodialysis patients with secondary hyperparathyroidism, abdominal aortic calcification decreased more in patients who underwent parathyroidectomy than in those in a control group over 1 year.
VDRAs Do Not Lower Cardiovascular Event Risk in HD
Trial results do not support use of vitamin D receptor activators to prevent cardiovascular events in patients with end-stage renal disease and low intact parathyroid hormone levels.
An ESRD Patient With Uncontrolled Secondary Hyperparathyroidism
This is a case involving a 64-year-old woman with end-stage renal disease (ESRD) due to lupus nephritis who has been on hemodialysis for 7 years. She also has dementia, hypertension, obstructive sleep apnea on CPAP, and stage 1 non-small cell lung cancer post wedge resection. Over the past 12 months, her secondary hyperparathyroidism (SHPT) has…
Etelcalcetide Found to Increase Bone Mineral Density in SHPT
Markers of bone resorption decreased in hemodialysis patients with 6 months of etelcalcetide treatment.
Ankle-Brachial Index Predicts Vascular Calcification in SHPT
Analyses demonstrated that an ABI of 1.79 correlated with radiographic evidence of calcified vessels.
Thrice-Weekly Calcimimetic Dosing Feasible for SHPT
In a study, patients receiving cinacalcet under supervision 3 times per week after dialysis rather than after daily self-administration showed improvement in their parathyroid hormone levels.
Next post in Kidney Week 2018
